Recently, the protease activity of MALT1 has received particular attention as a drug target for the treatment of ABC DLBCL, a particularly aggressive form of human B-cell lymphoma that is dependent on the oncogenic activation of the CARMA1-BCL10-MALT1 pathway [23]–[25] and on the protease activity of MALT1 [26]–[29]. Here, MALT1 is linked to B-cell non-Hodgkin lymphoma.